Stage IIIC Cutaneous Melanoma AJCC v7 Recruiting Phase 1 Trials for Ipilimumab (DB06186)

IndicationStatusPhase
DBCOND0091049 (Stage IIIC Cutaneous Melanoma AJCC v7)Recruiting1
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT03425461Anti-SEMA4D Monoclonal Antibody VX15/2503 With Nivolumab or Ipilimumab in Treating Patients With Stage III or IV MelanomaTreatment